Inventiva Reports Preliminary H1 2024 Cash And Cash Equivalents At €10.1 Million As Of June 30, 2024, No Revenues Recorded
Portfolio Pulse from Benzinga Newsdesk
Inventiva reported preliminary H1 2024 cash and cash equivalents at €10.1 million as of June 30, 2024, with no revenues recorded. This is a significant decrease from €26.9 million in cash and equivalents at the end of 2023. On July 18, 2024, Inventiva issued royalty certificates subscribed by Samsara BioCapital and existing shareholders for approximately €20.1 million.
July 31, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Inventiva's cash and cash equivalents have significantly decreased to €10.1 million as of June 30, 2024, from €26.9 million at the end of 2023. The company recorded no revenues in H1 2024, compared to €1.9 million in the same period in 2023. However, Inventiva issued royalty certificates worth €20.1 million in July 2024.
The significant decrease in cash and cash equivalents and the absence of revenues for H1 2024 are negative indicators for Inventiva's financial health. Although the issuance of €20.1 million in royalty certificates provides some liquidity, the overall financial position appears weakened.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100